David Clifton’s Post

From MassDevice: Asensus Surgical has entered a non-binding letter of intent with KARL STORZ, proposing the acquisition of all issued and outstanding Asensus shares at a 66.7% premium, priced at 35¢ each, marking Karl Storz's "best and final offer." The agreement initiates a 10-week exclusivity period during which Asensus will not seek alternative transactions, allowing Karl Storz to conduct due diligence and negotiate a merger, with both parties retaining the right to terminate discussions. Additionally, Asensus has secured a bridge loan of up to $20 million from Karl Storz to support operations during and potentially beyond this period, with both companies committed to diligently working towards finalizing a merger agreement and seeking stockholder approval. #MedTech #SurgicalRobot #MedicalDevices #Merger #Senhance #Luna

Excited to hear about our upcoming Vascular portfolio expansion. Some highlights below: "Carotid artery disease, a buildup of plaque in the carotid arteries of the neck that decreases blood flow to the brain, is the cause of one-third of all strokes and a condition in which the carotid arteries in the neck become narrowed or blocked due to the buildup of plaque." "Silk Road’s products are the only commercially available devices for use during a minimally invasive procedure called transcarotid artery revascularization (TCAR) to treat patients with carotid artery disease" "In the procedure, a small incision is made in the neck to access the carotid artery to temporarily reverse blood flow away from the brain to prevent plaque from dislodging. A stent is then placed at the site of the blockage to stabilize the plaque for long-term stroke prevention."

I read the post below from Joe Mullings about the increased M&A activity in med device and how the large strategic players are going to add companies to their portfolios.  I completely agree with his take, many people in our med device community are going to have their professional experience impacted by M&A in 2024.  Here are some thoughts on how to manage yourself and lead teams in this time of uncertainty. I have been part of companies that so desperately wanted to be bought they basically burned the boats in anticipation of a transaction.  I also lead a team that focused on not being bought. “Beat the number every quarter and our valuation will be so high no one will buy us” was one of our mantras.    It worked pretty well from my perspective. Interesting enough, the same exact approach to leadership works in both circumstances.  M&A, and all the rumors that go with it, is an enormous consumer of organizational energy and can be a disastrous distraction to a company. Hyper focus from a leadership team is the best antidote to keep your organization performing. A great litmus test to measure organizational focus is to determine when people start thinking about their own self interest and stop concentrating on the health and success of the business.  If you spend your time thinking about your job security, how much money you might make or what your next promotion might be, you are doing yourself and your team a disservice. I was with an organization that was purchased by a large strategic player and nearly every day the sales force would call each other and spend time speculating, time that should have been spent on what’s important, driving the business forward and spending time with your loved ones.  Self-interest is the killer of organizational productivity. If you are leading a team, managing your own territory or any part of a corporate team, your job is to focus on what you can do today to move the business forward.  It is a natural desire to be in the know, to have access to meetings or information that are interesting and outside the normal doldrums of our everyday responsibilities and to indulge in speculation, both positive and negative. It not sexy or overly appealing to focus on your job or your team instead of thinking about what might happen, but it’s a bedrock of great leadership and a world class team. You may have read some of my posts about “A” Players and how they act and think.  Top performers know how to focus, focus, focus on what is important now.  They control the controllable and don’t spend time worrying about things they cannot influence.  Two final thoughts. Performing well in times of uncertainty will distinguish you and present career opportunities you haven’t imagined.    Finally, people crave security in times of change.  BE A GREAT LEADER.  Exercise high communication, consistency in tone and demeanor, continual encouragement and relentless focus on the objective.  People will notice.

Recent Mergers and Acquisitions - With M&As on a downswing, it’s only a matter of time before pent-up demand kicks in and we see a surge of new investments. A quick look at one of the top 3 M&A Deals (thus far in 2024) Johnson & Johnson acquisition of Shockwave Medical Date closed: May 31, 2024 Value: $13.1 billion Industry: Healthcare In the largest healthcare deal of the year so far, Johnson & Johnson paid out over $13 billion – made up of a mix of cash on hand and debt – to take over medical device manufacturer Shockwave Medical. This purchase will expand Johnson & Johnson’s portfolio of coronary artery disease (CAD) and peripheral artery disease (PAD) treatments, two fast growing segments of the healthcare market.

SPAC Feed: Yes, SPAC Mergers Still Exist in Medtech  Medical Device and Diagnostics Industry Source: Yes, SPAC Mergers Still Exist in Medtech –… - https://lnkd.in/eGbu63-B #SPACs #SPACNews #SPAC #IPO #markets #news #capitalmarkets #trends #goingpublic #finance #business

1. Stryker is the third-largest U.S. medical device company, focusing on acquisitions to enhance competitiveness. 2. Since July 2024, Stryker has announced or completed five acquisitions. 3. The company operates in two segments: MedSurg & Neurotechnology (58% of revenue) and Orthopedics & Spine (42% of revenue). 4. Key acquisitions include NICO, which offers minimally invasive devices for treating intracerebral hemorrhage, significantly reducing patient mortality rates. 5. The acquisition of care.ai enhances patient monitoring through AI, improving resource allocation in healthcare facilities. 6. While short-term financial impacts of these acquisitions are unclear, they may create long-term value for Stryker. 7. Analysts forecast a 12% annual growth in earnings per share for Stryker, outperforming main competitor Medtronic. 8. Stryker holds a "Moderate Buy" rating, but some analysts suggest better investment options are available.

J&J's Strategic Medtech Acquisitions Johnson & Johnson (J&J) is making notable strides in the medtech sector, reflected by a Q3 medtech sales of $7.89 billion, a 5.8% year-over-year increase. The cardiovascular group stood out with over 26% growth, significantly boosted by the acquisitions of Abiomed and Shockwave Medical. These two alone added nearly $2 billion to Q3 sales, with Abiomed contributing $362 million, a 16.3% year-over-year growth. These moves mark J&J's shift towards higher-growth, higher-margin categories. The recent $1.6 billion acquisition of V-Wave supports this strategy, strengthening their cardiovascular portfolio and balancing slower growth in other areas. J&J's CEO, Joaquin Duato, highlighted ongoing innovation efforts like the submission of an investigational device exemption application for the Ottava surgical robot. #MedTech #JohnsonAndJohnson #CardiovascularBusiness

The top #medtech trends in 2024 Experts have said that mergers and acquisitions, orthopaedic procedure backlogs and emerging cardiac markets are among the top trends to watch in the #medicaldevice industry this year. Find out more via MedTech Dive https://lnkd.in/e7KAmPrS

No more multi-billion dollar acquisitions, 2023 saw a sharp decline in the value of M&A deals in the MedTech industry. The total value of the top 10 M&A deals completed in 2023 was less than half of the previous year. Thank you, Andrew Thompson, for discussing the current and future trends in the sector. #ai, #2023trends #medicaldevices #mergersandacquisitions https://lnkd.in/etyqD85t

Here's a snapshot of some major mergers and acquisitions in the medical devices sector in 2024: Medtronic and Mazor Robotics: The acquisition value was approximately $1.6 billion. Boston Scientific and Apollo Endosurgery: Boston Scientific acquired Apollo Endosurgery for around $1.5 billion. Stryker and Wright Medical: The total deal value for Wright Medical was about $5.4 billion, although this acquisition was finalized in 2020, it continues to impact the industry in 2024. Zimmer Biomet and Acelity: Zimmer Biomet's acquisition of Acelity was valued at approximately $2.4 billion. Johnson & Johnson and Abiomed: Johnson & Johnson acquired Abiomed for around $16.6 billion. These figures illustrate the significant financial stakes involved in consolidating and expanding portfolios in the medical device sector.